NCT05063916
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 8 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: \<75% participation Show 5 more changesShow less
- Eligibility criteria expanded, about 50 words
- Primary endpoints: details revised at 1 of 1 entry
- Final enrollment: 9 participants (planned 18)
- Primary completion date changed from estimate of Aug 1, 2027 to Nov 11, 2026
- Study description expanded, about 4 words
- Notable Primary and study completion dates: Aug 1, 2025 to Aug 1, 2027v15
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary and study completion dates: Sep 1, 2023 to Aug 1, 2025v8
- Notable Primary and study completion dates: Aug 1, 2025 to Sep 1, 2023v7
Show 2 earlier versionsHide 2 earlier versions
- Notable Primary and study completion dates: Aug 1, 2023 to Aug 1, 2025v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria shortened, about 1 word
- Start date changed from estimate of Mar 31, 2022 to Feb 28, 2022
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To establish the progression free survival rate at 6 months (PFS6) in response to AK104 monotherapy in patients with progressive/relapsed high-grade neuroendocrine carcinomas of the cervix
Timeframe: (up to 6 months) through study completion, an average of 1 year
Arms and interventions
AK104Experimental
cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).
Drugs: AK104
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States